Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells

Experimental Hematology

Volumn 37, Issue 3, 2009, Pages 395-401

  Hamilton, Ashley ^a   Alhashimi, Fatma ^a   Myssina, Svetlana ^a   Jorgensen, Heather G ^a   Holyoake, Tessa L ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; CRK LIKE PROTEIN;

ACCURACY; ARTICLE; BCR ABL FUSION GENE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FUSION GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; TECHNIQUE; VALIDATION PROCESS; WESTERN BLOTTING; WILD TYPE;

ENZYME-LINKED IMMUNOSORBENT ASSAY; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METHODS; PHOSPHORYLATION; RESEARCH DESIGN; TYROSINE;

EID: 59949099663     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.11.005     Document Type: Article

References (28)

1. Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973) 290-293
2. Groffen J., Stephenson J.R., Heisterkamp N., de Klein A., Bartram C.R., and Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36 (1984) 93-99
3. Ben-Neriah Y., Daley G.Q., Mes-Masson A.M., Witte O.N., and Baltimore D. The chronic myelogenous leukaemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233 (1986) 212-214
4. Steelman L.S., Pohnert S.C., Shelton J.G., Franklin R.A., Bertrand F.E., and McCubrey J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18 (2004) 189-218
5. Oda T., Heaney C., Hagopian J.R., Okuda K., Griffin J.D., and Druker B.J. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 269 (1994) 22925-22928
6. Coulombel L., Kalousek D.K., Eaves C.J., Gupta C.M., and Eaves A.C. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome positive chronic myelogenous leukemia. N Engl J Med 308 (1983) 1493-1498
7. Frassoni F., Podesta M., and Piaggio G. Normal and leukaemic haematopoiesis in bone marrow and peripheral blood of patients with chronic myeloid leukaemia. Baillieres Best Pract Res Clin Haematol 12 (1999) 199-208
8. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
9. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
10. Hamilton A., Elrick L., Myssina S., et al. BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia 20 (2006) 1035-1039
11. Copland M., Hamilton A., Elrick L.J., et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107 (2006) 4532-4539
12. Lombardo L.J., Lee F.Y., Chen P., et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-yla mino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47 (2004) 6658-66561
13. Weisberg E., Manley P.W., Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
14. Golas J.M., Arndt K., Etienne C., et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63 (2003) 375-381
15. White D., Saunders V., Lyons A.B., et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 106 (2005) 2520-2526
16. Hochhaus A., Kreil S., Corbin A., et al. Roots of clinical resistance to STI-571 cancer therapy. Science 293 (2001) 2163
17. Cortes J., Jabbour E., Kantarjian H., et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110 (2007) 4005-4011
18. Rousselot P., Huguet F., Rea D., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109 (2007) 58-60
19. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006) 2408-2417
20. Graham S.M., Jorgensen H.G., Allan E., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99 (2002) 319-325
21. Jørgensen H.G., Allan E.K., Jordanides N.E., Mountford J.C., and Holyoake T.L. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109 (2007) 4016-4019
22. Konig H., Holtz M., Modi H., et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 22 (2008) 748-755
23. Konig H., Holyoake T.L., and Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 111 (2008) 2329-2338
24. Schultheis B., Szydlo R., Mahon F.X., Apperley J.F., and Melo J.V. Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. Blood 105 (2005) 4893-4894
25. Maxwell S.A., Kurzrock R., Parsons S.J., et al. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. Cancer Res 47 (1987) 1731-1739
26. Patel H., Marley S.B., and Gordon M.Y. Conventional Western blotting techniques will not reliably quantify p210BCR-ABL1 levels in CML mononuclear cells. Blood 109 (2007) 1335
27. Patel H., Marley S.B., and Gordon M.Y. Detection in primary chronic myeloid leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, and GRB2. Genes Chromosomes Cancer 45 (2006) 1121-1129
28. Singer C.F., Hudelist G., Lamm W., et al. Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. Oncol Rep 15 (2006) 353-359